[Doxapram. Pharmocokinetic and clinical study].
Two series of work are reported. The first concerns the pharmacocinetic study of the product after it was administered through different ways and the corresponding evolution of PaCO2. The second study concerns the effect on pulmonary arterial pressure, blood gases and some parameters of ventilatory mechanics, of a perfusion of 200 mg of this product over a two hours period.
D000284:Administration, Oral; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D004315:Doxapram / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D011651:Pulmonary Artery / Q000502:physiology; D012119:Respiration / Q000187:drug effects; D012131:Respiratory Insufficiency / Q000188:drug therapy*; D013488:Suppositories
D013488:Suppositories; D002245:Carbon Dioxide; D004315:Doxapram
Le doxapram. Etude pharmacocinétique et clinique.